Ultragenyx Pharmaceutical | RARE - Equity Capital And Reserves


Ultragenyx Pharmaceutical reported $-236M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Immunic USD 151.23M 157.91M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Kyowa Hakko Kirin JPY 892.74B 591M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xoma USD 87.94M 15.5M Sep/2025